Artificial Intelligence (AI) In Drug Discovery Market - Global Industry Analysis

Market Overview

In terms of revenue, the global Artificial Intelligence (AI) In Drug Discovery Market accounted for USD 261 Million in 2020 and is expected to reach USD 3,493 Million by 2028, growing at a CAGR of 38.3% from 2021 to 2028.

AI is getting sophisticated at doing what humans do, but in efficient, quicker manner and at a lower cost. The potential for both Artificial Intelligence in healthcare is vast. The AI has the potential to help researchers create drugs as well. Various robot scientists using AI can test more compounds with improved accuracy, reproducibility and exhaustive record keeping. With the decline in new drug discovery rate and rise in expenditure for drug trials, companies are now switching to AI platforms for drug inventions and drug trials. Machine learning and natural language processing are two AI platforms used in drug discovery. AI virtually screens the molecule, designs molecule model, analyses and predicts how likely a drug is to have right properties to be non-toxic in the body.  

Various AI solutions are being developed to identify new potential therapies from vast databases of information on existing medicines, which could be redesigned to target critical diseases such as the Ebola virus. This could improve the efficiency and success rate of drug development, stimulating the process to bring new drugs to market in response to deadly disease threats.

Several research organizations are using artificial intelligence in drug design. For instance, in 2016, IBM Waton partnered with Pfizer in their drug discovery research. Pfizer is using IBM Watson to identify new drugs for their immune-oncology research. GNS Healthcare has partnered with Genentech, a member of the Roche group, to use machine learning for drug discovery. Their focus is on developing personalized medicine approaches using AI, especially for cancer treatments. Sanofi has signed a deal to use UK start-up Exscientia’s artificial-intelligence (AI) platform to search for metabolic-disease therapies.

COVID-19 Impact Analysis

Outbreak of novel coronavirus disease became pandemic and has disastrously affected world economics. Effect of COVID-19 on the global economy is so huge that all the sectors are suffering backlash including pharmaceutical, biotechnology, and AI sectors. While suffering through the impact, many pharmaceutical, biopharmaceutical, and AI companies are supporting regional governments to address the unmet COVID-19 needs, which has started putting financial burden on research & development sector. COVID-19 impact on pharmaceutical and biopharmaceutical sector starts right from disruption in research & development activities and goes till the very end of pharmaceutical products supply chain, which has severely hampered demand for AI in drug discovery. Whether the supply chain is integral or outsourced, it is handling immense pressure. Supply of the pharmaceutical drugs and other pharmaceutical products has narrowed down while the demand is burgeoning, creating a huge demand-supply gap.

COVID-19 impact on all the application sectors of AI including imaging diagnostics, drug discovery, lifestyle management & monitoring, emergency room and hospital management, wearables, insights & risk analytics, and virtual assistance has severely impacted global artificial intelligence market.

Growth Factors

Healthcare sector is being transformed with the emergence of AI, which offers the ability to manage massive amounts of valuable data about hits, molecules, and clinical trial subjects, which may be impossible for human beings to analyze. Here, AI offers a technique to automatically find patterns about data, which enables researchers to focus on the essential part of drug discovery by effectively managing time and minimizing errors.

Technological advances in the drug discovery processes and innovations have revolutionized the field of oncology and given birth to highly effective treatment options. Several diagnostic techniques such as CT scans, 3D mammograms, and targeted radiation therapy have enhanced the understanding of cancer with early and effective diagnosis. Moreover, constantly growing investments in oncology drugs R&D and huge expenditure by leading pharmaceutical and biotechnology companies on better outputs are giving a push to the overall AI in drug discovery market growth. Growing emphasis on the research & development of oncology drugs is expected to benefit the global AI in drug discovery market growth.

Financial challenge is affecting the potential of artificial intelligence in health care sector worldwide, As the AI technology is in the nascent stage and various organizations and players are still in R&D phase over its implementation in their products and services depends on funding. Hence, these are some factors which can act as restrain to the global AI in drug discovery market.

Report Scope:

Drug Type Segment Analysis Preview:

On the basis of drug types, the market is segmented into small molecule and large molecule. Large molecule holds the major share in the market. Large molecules are large and complex, generally consisting heterogeneous mixtures. Manufacturing of the large molecules is more challenging than for traditional small molecules drugs. Even minor changes in the manufacturing process, results in severe or significant changes in the immunogenicity or efficacy. Discovery for large molecules is generally expensive than that of small molecule. Being expensive, adoption of the large molecules has lowered in the last few years, hampering the segment growth.

Combining the efficacies of therapies and treatments, small molecule drug types are expected to drive the overall AI in drug discovery market. With significant development in overall therapies and treatment options, small molecules are expected to outgrow the efficacies of large molecules and takeover the AI in drug discovery. Small molecules are expected to benefit from their cross-membrane ability to reach the greater intracellular targets. Increased level of efficacy of the small molecule through extensive research & development is expected to boost the overall small molecule segment in global AI in drug discovery market.

End-User Segment Analysis Preview:

On the basis of end user, the global market is segmented into pharmaceutical & biopharmaceutical companies, academic & research institutions, and others. Pharmaceutical companies such as GlaxoSmithKline, Pfizer, AstraZeneca, and Eli Lilly & Company are implementing AI to streamline the whole drug development process. AI is also used to predict adverse drug reactions among patents. Hence, pharmaceutical & biopharmaceutical companies, academic & research institutions are anticipated to boost the overall End-User segment in global AI in drug discovery market.

Regional Analysis Preview

North America holds the largest share in market for AI in drug discovery owing to technological advancements and early adoption of artificial intelligence platforms in developed countries such as the U.S. and Canada. North America is one of the most technologically advanced application markets for AI due to the active involvement of tech giants in the field of artificial intelligence. Moreover, high adoption rate of AI in North America coupled with development & growth of research & development activities and investments by government and private organizations in the pharmaceutical and biotechnology companies is further stimulating the market growth.

Furthermore, increasing prevalence of various chronic, metabolic, infectious, and life threatening diseases has boosted demand for novel treatment therapies and drugs through AI in drug discovery, fueling the overall North American AI in drug discovery market.

Asia-Pacific region is anticipated to grow at fastest CAGR of XX% over the forecast period. Growing population, increasing patient pool base, rising adoption of cloud computing techniques, growing aged population, and various government initiatives favoring AI for drug discovery are the major driving factors for regional market.

Key Market Players & Competitive Landscape

Some of key players in Artificial Intelligence (AI) In Drug Discovery Market are,

1. IBM Corporation
2. Microsoft
3. Google
4. NVIDIA Corporation
5. Atomwise, Inc.
6. Deep Genomics
7. Cloud Pharmaceuticals
8. Insilico Medicine
9. Benevolent AI
10. Exscientia
11. Cyclica
12. BIOAGE

The Artificial Intelligence (AI) In Drug Discovery Market is segmented as follows:

By Drug Type

• Large Molecule
• Small Molecule

By Offering

• Software
• Services

By Application

• Immuno-oncology
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Other Applications     

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Research Centers and Academic & Government Institutes

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

• CHAPTER NO. 1. INTRODUCTION
  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. USP & Key Offerings
  • 1.2. Key Benefits for Stakehulders
  • 1.3. Target Audience
  • 1.4. Report Scope
• CHAPTER NO. 2. EXECUTIVE SUMMARY
  • 2.1. Key Findings
    • 2.1.1. Top Investment Pockets
      • 2.1.1.1. Market Attractiveness Analysis, By Drug Type
      • 2.1.1.2. Market Attractiveness Analysis, By Offering
      • 2.1.1.3. Market Attractiveness Analysis, By Application
      • 2.1.1.4. Market Attractiveness Analysis, By End User
      • 2.1.1.5. Market Attractiveness Analysis, By Region
  • 2.2. Market Snapshot
  • 2.3. Global Artificial Intelligence (AI) In Drug Discovery Market, 2016 – 2028 (USD Million)
  • 2.4. Insights from Primary Respondents
• CHAPTER NO. 3. COVID 19 IMPACT ANALYSIS
  • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. The Middle-East and Africa
  • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
  • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
  • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
  • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
    • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
  • 3.6. Short Term Dynamics
  • 3.7. Long Term Dynamics
• CHAPTER NO. 4. ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET – BY DRUG TYPE SEGMENT ANALYSIS
  • 4.1. Overview
    • 4.1.1. Market Revenue Share, By Drug Type, 2020 & 2028
  • 4.2. Large Mulecules
    • 4.2.1. Market Size and Forecast, By Region (USD Million)
    • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.3. Small Mulecules
    • 4.3.1. Market Size and Forecast, By Region (USD Million)
    • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 5. ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET – OFFERING SEGMENT ANALYSIS
  • 5.1. Overview
    • 5.1.1. Market Revenue Share, By Offering, 2020 & 2028
  • 5.2. Software
    • 5.2.1. Market Size and Forecast, By Region (USD Million)
    • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 5.3. Services
    • 5.3.1. Market Size and Forecast, By Region (USD Million)
    • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 6. ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET – APPLICATION SEGMENT ANALYSIS
  • 6.1. Overview
    • 6.1.1. Market Revenue Share, By Application, 2020 & 2028
  • 6.2. Immuno-onculogy
    • 6.2.1. Market Size and Forecast, By Region (USD Million)
    • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 6.3. Neurodegenerative Diseases
    • 6.3.1. Market Size and Forecast, By Region (USD Million)
    • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
  • 6.4. Cardiovascular Diseases
    • 6.4.1. Market Size and Forecast, By Region (USD Million)
    • 6.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 6.4.3. Key Market Trends, Growth Factors, & Opportunities
  • 6.5. Metabulic Diseases
    • 6.5.1. Market Size and Forecast, By Region (USD Million)
    • 6.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 6.5.3. Key Market Trends, Growth Factors, & Opportunities
  • 6.6. Other Applications
    • 6.6.1. Market Size and Forecast, By Region (USD Million)
    • 6.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 6.6.3. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 7. ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET – END USER SEGMENT ANALYSIS
  • 7.1. Overview
    • 7.1.1. Market Revenue Share, By End User, 2020 & 2028
  • 7.2. Pharmaceutical & Biotechnulogy Companies
    • 7.2.1. Market Size and Forecast, By Region (USD Million)
    • 7.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 7.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 7.3. Contract Research Organizations
    • 7.3.1. Market Size and Forecast, By Region (USD Million)
    • 7.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 7.3.3. Key Market Trends, Growth Factors, & Opportunities
  • 7.4. Research Centers and Academic & Government Institutes
    • 7.4.1. Market Size and Forecast, By Region (USD Million)
    • 7.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 7.4.3. Key Market Trends, Growth Factors, & Opportunities
• CHAPTER NO. 8. ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET – REGIONAL ANALYSIS
  • 8.1. Overview
    • 8.1.1. Global Market Revenue Share, By Region, 2020 & 2028
    • 8.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 8.2.2. North America Market Revenue, By Drug Type, 2016 – 2028
    • 8.2.3. North America Market Revenue, By Offering, 2016 – 2028
    • 8.2.4. North America Market Revenue, By Application, 2016 – 2028
    • 8.2.5. North America Market Revenue, By End User, 2016 – 2028
    • 8.2.6. U.S.
      • 8.2.6.1. U.S. Market Revenue, By Drug Type, 2016 – 2028
      • 8.2.6.2. U.S. Market Revenue, By Offering, 2016 – 2028
      • 8.2.6.3. U.S. Market Revenue, By Application, 2016 – 2028
      • 8.2.6.4. U.S. Market Revenue, By End User, 2016 – 2028
    • 8.2.7. Canada
      • 8.2.7.1. Canada Market Revenue, By Drug Type, 2016 – 2028
      • 8.2.7.2. Canada Market Revenue, By Offering, 2016 – 2028
      • 8.2.7.3. Canada Market Revenue, By Application, 2016 – 2028
      • 8.2.7.4. Canada Market Revenue, By End User, 2016 – 2028
    • 8.2.8. Mexico
      • 8.2.8.1. Mexico Market Revenue, By Drug Type, 2016 – 2028
      • 8.2.8.2. Mexico Market Revenue, By Offering, 2016 – 2028
      • 8.2.8.3. Mexico Market Revenue, By Application, 2016 – 2028
      • 8.2.8.4. Mexico Market Revenue, By End User, 2016 – 2028
  • 8.3. Europe
    • 8.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 8.3.2. Europe Market Revenue, By Drug Type, 2016 – 2028
    • 8.3.3. Europe Market Revenue, By Offering, 2016 – 2028
    • 8.3.4. Europe Market Revenue, By Application, 2016 – 2028
    • 8.3.5. Europe Market Revenue, By End User, 2016 – 2028
    • 8.3.6. Germany
      • 8.3.6.1. Germany Market Revenue, By Drug Type, 2016 – 2028
      • 8.3.6.2. Germany Market Revenue, By Offering, 2016 – 2028
      • 8.3.6.3. Germany Market Revenue, By Application, 2016 – 2028
      • 8.3.6.4. Germany Market Revenue, By End User, 2016 – 2028
    • 8.3.7. France
      • 8.3.7.1. France Market Revenue, By Drug Type, 2016 – 2028
      • 8.3.7.2. France Market Revenue, By Offering, 2016 – 2028
      • 8.3.7.3. France Market Revenue, By Application, 2016 – 2028
      • 8.3.7.4. France Market Revenue, By End User, 2016 – 2028
    • 8.3.8. U.K.
      • 8.3.8.1. U.K. Market Revenue, By Drug Type, 2016 – 2028
      • 8.3.8.2. U.K. Market Revenue, By Offering, 2016 – 2028
      • 8.3.8.3. U.K. Market Revenue, By Application, 2016 – 2028
      • 8.3.8.4. U.K. Market Revenue, By End User, 2016 – 2028
    • 8.3.9. Italy
      • 8.3.9.1. Italy Market Revenue, By Drug Type, 2016 – 2028
      • 8.3.9.2. Italy Market Revenue, By Offering, 2016 – 2028
      • 8.3.9.3. Italy Market Revenue, By Application, 2016 – 2028
      • 8.3.9.4. Italy Market Revenue, By End User, 2016 – 2028
    • 8.3.10. Spain
      • 8.3.10.1. Spain Market Revenue, By Drug Type, 2016 – 2028
      • 8.3.10.2. Spain Market Revenue, By Offering, 2016 – 2028
      • 8.3.10.3. Spain Market Revenue, By Application, 2016 – 2028
      • 8.3.10.4. Spain Market Revenue, By End User, 2016 – 2028
    • 8.3.11. Rest of Europe
      • 8.3.11.1. Rest of Europe Market Revenue, By Drug Type, 2016 – 2028
      • 8.3.11.2. Rest of Europe Market Revenue, By Offering, 2016 – 2028
      • 8.3.11.3. Rest of Europe Market Revenue, By Application, 2016 – 2028
      • 8.3.11.4. Rest of Europe Market Revenue, By End User, 2016 – 2028
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 8.4.2. Asia Pacific Market Revenue, By Drug Type, 2016 – 2028
    • 8.4.3. Asia Pacific Market Revenue, By Offering, 2016 – 2028
    • 8.4.4. Asia Pacific Market Revenue, By Application, 2016 – 2028
    • 8.4.5. Asia Pacific Market Revenue, By End User, 2016 – 2028
    • 8.4.6. China
      • 8.4.6.1. China Market Revenue, By Drug Type, 2016 – 2028
      • 8.4.6.2. China Market Revenue, By Offering, 2016 – 2028
      • 8.4.6.3. China Market Revenue, By Application, 2016 – 2028
      • 8.4.6.4. China Market Revenue, By End User, 2016 – 2028
    • 8.4.7. Japan
      • 8.4.7.1. Japan Market Revenue, By Drug Type, 2016 – 2028
      • 8.4.7.2. Japan Market Revenue, By Offering, 2016 – 2028
      • 8.4.7.3. Japan Market Revenue, By Application, 2016 – 2028
      • 8.4.7.4. Japan Market Revenue, By End User, 2016 – 2028
    • 8.4.8. India
      • 8.4.8.1. India Market Revenue, By Drug Type, 2016 – 2028
      • 8.4.8.2. India Market Revenue, By Offering, 2016 – 2028
      • 8.4.8.3. India Market Revenue, By Application, 2016 – 2028
      • 8.4.8.4. India Market Revenue, By End User, 2016 – 2028
    • 8.4.9. South Korea
      • 8.4.9.1. South Korea Market Revenue, By Drug Type, 2016 – 2028
      • 8.4.9.2. South Korea Market Revenue, By Offering, 2016 – 2028
      • 8.4.9.3. South Korea Market Revenue, By Application, 2016 – 2028
      • 8.4.9.4. South Korea Market Revenue, By End User, 2016 – 2028
    • 8.4.10. South-East Asia
      • 8.4.10.1. South-East Asia Market Revenue, By Drug Type, 2016 – 2028
      • 8.4.10.2. South-East Asia Market Revenue, By Offering, 2016 – 2028
      • 8.4.10.3. South-East Asia Market Revenue, By Application, 2016 – 2028
      • 8.4.10.4. South-East Asia Market Revenue, By End User, 2016 – 2028
    • 8.4.11. Rest of Asia Pacific
      • 8.4.11.1. Rest of Asia Pacific Market Revenue, By Drug Type, 2016 – 2028
      • 8.4.11.2. Rest of Asia Pacific Market Revenue, By Offering, 2016 – 2028
      • 8.4.11.3. Rest of Asia Pacific Market Revenue, By Application, 2016 – 2028
      • 8.4.11.4. Rest of Asia Pacific Market Revenue, By End User, 2016 – 2028
  • 8.5. Latin America
    • 8.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 8.5.2. Latin America Market Revenue, By Drug Type, 2016 – 2028
    • 8.5.3. Latin America Market Revenue, By Offering, 2016 – 2028
    • 8.5.4. Latin America Market Revenue, By Application, 2016 – 2028
    • 8.5.5. Latin America Market Revenue, By End User, 2016 – 2028
    • 8.5.6. Brazil
      • 8.5.6.1. Brazil Market Revenue, By Drug Type, 2016 – 2028
      • 8.5.6.2. Brazil Market Revenue, By Offering, 2016 – 2028
      • 8.5.6.3. Brazil Market Revenue, By Application, 2016 – 2028
      • 8.5.6.4. Brazil Market Revenue, By End User, 2016 – 2028
    • 8.5.7. Argentina
      • 8.5.7.1. Argentina Market Revenue, By Drug Type, 2016 – 2028
      • 8.5.7.2. Argentina Market Revenue, By Offering, 2016 – 2028
      • 8.5.7.3. Argentina Market Revenue, By Application, 2016 – 2028
      • 8.5.7.4. Argentina Market Revenue, By End User, 2016 – 2028
    • 8.5.8. Rest of Latin America
      • 8.5.8.1. Rest of Latin America Market Revenue, By Drug Type, 2016 – 2028
      • 8.5.8.2. Rest of Latin America Market Revenue, By Offering, 2016 – 2028
      • 8.5.8.3. Rest of Latin America Market Revenue, By Application, 2016 – 2028
      • 8.5.8.4. Rest of Latin America Market Revenue, By End User, 2016 – 2028
  • 8.6. The Middle-East and Africa
    • 8.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 8.6.2. The Middle-East and Africa Market Revenue, By Drug Type, 2016 – 2028
    • 8.6.3. The Middle-East and Africa Market Revenue, By Offering, 2016 – 2028
    • 8.6.4. The Middle-East and Africa Market Revenue, By Application, 2016 – 2028
    • 8.6.5. The Middle-East and Africa Market Revenue, By End User, 2016 – 2028
    • 8.6.6. GCC Countries
      • 8.6.6.1. GCC Countries Market Revenue, By Drug Type, 2016 – 2028
      • 8.6.6.2. GCC Countries Market Revenue, By Offering, 2016 – 2028
      • 8.6.6.3. GCC Countries Market Revenue, By Application, 2016 – 2028
      • 8.6.6.4. GCC Countries Market Revenue, By End User, 2016 – 2028
    • 8.6.7. South Africa
      • 8.6.7.1. South Africa Market Revenue, By Drug Type, 2016 – 2028
      • 8.6.7.2. South Africa Market Revenue, By Offering, 2016 – 2028
      • 8.6.7.3. South Africa Market Revenue, By Application, 2016 – 2028
      • 8.6.7.4. South Africa Market Revenue, By End User, 2016 – 2028
    • 8.6.8. Rest of Middle-East Africa
      • 8.6.8.1. Rest of Middle-East Africa Market Revenue, By Drug Type, 2016 – 2028
      • 8.6.8.2. Rest of Middle-East Africa Market Revenue, By Offering, 2016 – 2028
      • 8.6.8.3. Rest of Middle-East Africa Market Revenue, By Application, 2016 – 2028
      • 8.6.8.4. Rest of Middle-East Africa Market Revenue, By End User, 2016 – 2028
• CHAPTER NO. 9. ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET – INDUSTRY ANALYSIS
  • 9.1. Introduction
  • 9.2. Market Drivers
    • 9.2.1. Driving Factor 1 Analysis
    • 9.2.2. Driving Factor 2 Analysis
  • 9.3. Market Restraints
    • 9.3.1. Restraining Factor Analysis
  • 9.4. Market Opportunities
    • 9.4.1. Market Opportunity Analysis
  • 9.5. Porter’s Five Forces Analysis
  • 9.6. PEST Analysis
  • 9.7. Regulatory Landscape
  • 9.8. Technology Landscape
  • 9.9. Regional Market Trends
    • 9.9.1. North America
    • 9.9.2. Europe
    • 9.9.3. Asia Pacific
    • 9.9.4. Latin America
    • 9.9.5. The Middle-East and Africa
  • 9.10. Pricing Analysis
  • 9.11. Value Chain Analysis
  • 9.12. Downstream Buyers
  • 9.13. Distributors/Traders List
• CHAPTER NO. 10. COMPETITIVE LANDSCAPE
  • 10.1. Company Market Share Analysis – 2019
    • 10.1.1. Global Artificial Intelligence (AI) In Drug Discovery Market: Company Market Share, 2019
    • 10.1.2. Global Artificial Intelligence (AI) In Drug Discovery Market, Company Market Revenue, 2016 – 2019 (USD Million)
    • 10.1.3. Global Artificial Intelligence (AI) In Drug Discovery Market, Company Y-o-Y Growth, 2017 – 2019 (%)
    • 10.1.4. Global Artificial Intelligence (AI) In Drug Discovery Market: Radar Determinant Chart, 2019
  • 10.2. Strategic Developments
    • 10.2.1. Acquisitions & Mergers
    • 10.2.2. New Product Launch
    • 10.2.3. Regional Expansion
  • 10.3. Company Strategic Developments – Heat Map Analysis
• CHAPTER NO. 11. COMPANY PROFILES
  • 11.1. IBM Corporation
    • 11.1.1. Company Overview
    • 11.1.2. Key Executives
    • 11.1.3. Product Portfolio
    • 11.1.4. Financial Overview
    • 11.1.5. Operating Business Segments
    • 11.1.6. Business Performance
    • 11.1.7. Recent Developments
  • 11.2. Microsoft
  • 11.3. Google
  • 11.4. NVIDIA Corporation
  • 11.5. Atomwise, Inc.
  • 11.6. Deep Genomics
  • 11.7. Cloud Pharmaceuticals
  • 11.8. Insilico Medicine
  • 11.9. Benevulent AI
  • 11.10. Exscientia
  • 11.11. Cyclica
  • 11.12. BIOAGE
• CHAPTER NO. 12. MARKETING STRATEGY ANALYSIS
  • 12.1. Marketing Channel
  • 12.2. Direct Marketing
  • 12.3. Indirect Marketing
  • 12.4. Marketing Channel Development Trends
  • 12.5. Economic/Pulitical Environmental Change
• CHAPTER NO. 13. RESEARCH METHODulOGY
  • 13.1. Research Methodology
  • 13.2. Phase I - Secondary Research
  • 13.3. Phase II - Data Modeling
    • 13.3.1. Company Share Analysis Model
    • 13.3.2. Revenue Based Modeling
  • 13.4. Phase III - Primary Research
  • 13.5. Research Limitations
    • 13.5.1. Assumptions

Table Of Figures

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Drug Type
FIG NO. 2. Market Attractiveness Analysis, By Offering
FIG NO. 3. Market Attractiveness Analysis, By Application
FIG NO. 4. Market Attractiveness Analysis, By End User
FIG NO. 5. Market Attractiveness Analysis, By Region
FIG NO. 6. Global Artificial Intelligence (AI) In Drug Discovery Market Revenue, 2016 – 2028 (USD Million)
FIG NO. 7. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 8. Market Revenue Share, By Drug Type, 2020 & 2028
FIG NO. 9. Global Artificial Intelligence (AI) In Drug Discovery Market for Large Molecules, Revenue (USD Million) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Large Molecules, By Country, 2020 & 2028
FIG NO. 11. Global Artificial Intelligence (AI) In Drug Discovery Market for Small Molecules, Revenue (USD Million) 2016 – 2028
FIG NO. 12. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Small Molecules, By Country, 2020 & 2028
FIG NO. 13. Market Revenue Share, By Offering, 2020 & 2028
FIG NO. 14. Global Artificial Intelligence (AI) In Drug Discovery Market for Software, Revenue (USD Million) 2016 – 2028
FIG NO. 15. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Software, By Country, 2020 & 2028
FIG NO. 16. Global Artificial Intelligence (AI) In Drug Discovery Market for Services, Revenue (USD Million) 2016 – 2028
FIG NO. 17. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Services, By Country, 2020 & 2028
FIG NO. 18. Market Revenue Share, By Application, 2020 & 2028
FIG NO. 19. Global Artificial Intelligence (AI) In Drug Discovery Market for Immuno-oncology, Revenue (USD Million) 2016 – 2028
FIG NO. 20. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Immuno-oncology, By Country, 2020 & 2028
FIG NO. 21. Global Artificial Intelligence (AI) In Drug Discovery Market for Neurodegenerative Diseases, Revenue (USD Million) 2016 – 2028
FIG NO. 22. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Neurodegenerative Diseases, By Country, 2020 & 2028
FIG NO. 23. Global Artificial Intelligence (AI) In Drug Discovery Market for Cardiovascular Diseases, Revenue (USD Million) 2016 – 2028
FIG NO. 24. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Cardiovascular Diseases, By Country, 2020 & 2028
FIG NO. 25. Global Artificial Intelligence (AI) In Drug Discovery Market for Metabolic Diseases, Revenue (USD Million) 2016 – 2028
FIG NO. 26. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Metabolic Diseases, By Country, 2020 & 2028
FIG NO. 27. Global Artificial Intelligence (AI) In Drug Discovery Market for Other Applications, Revenue (USD Million) 2016 – 2028
FIG NO. 28. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Other Applications, By Country, 2020 & 2028
FIG NO. 29. Market Revenue Share, By End User, 2020 & 2028
FIG NO. 30. Global Artificial Intelligence (AI) In Drug Discovery Market for Pharmaceutical & Biotechnology Companies, Revenue (USD Million) 2016 – 2028
FIG NO. 31. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Pharmaceutical & Biotechnology Companies, By Country, 2020 & 2028
FIG NO. 32. Global Artificial Intelligence (AI) In Drug Discovery Market for Contract Research Organizations, Revenue (USD Million) 2016 – 2028
FIG NO. 33. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Contract Research Organizations, By Country, 2020 & 2028
FIG NO. 34. Global Artificial Intelligence (AI) In Drug Discovery Market for Research Centers and Academic & Government Institutes, Revenue (USD Million) 2016 – 2028
FIG NO. 35. Comparative Revenue Analysis of Artificial Intelligence (AI) In Drug Discovery Market for Research Centers and Academic & Government Institutes, By Country, 2020 & 2028
FIG NO. 36. Global Artificial Intelligence (AI) In Drug Discovery Market Revenue Share, By Region, 2020 & 2028
FIG NO. 37. North America Artificial Intelligence (AI) In Drug Discovery Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 38. Porter’s Five Forces Analysis for Global Artificial Intelligence (AI) In Drug Discovery Market
FIG NO. 39. PEST Analysis for Global Artificial Intelligence (AI) In Drug Discovery Market
FIG NO. 40. Pricing Analysis for Global Artificial Intelligence (AI) In Drug Discovery Market
FIG NO. 41. Value Chain Analysis for Global Artificial Intelligence (AI) In Drug Discovery Market
FIG NO. 42. Company Share Analysis, 2019
FIG NO. 43. Radar Determinant Chart, 2019
FIG NO. 44. Company Strategic Developments – Heat Map Analysis
FIG NO. 45. IBM Corporation Business Segment Revenue Share, 2020 (%)
FIG NO. 46. IBM Corporation Geographical Segment Revenue Share, 2020 (%)
FIG NO. 47. Market Channels
FIG NO. 48. Marketing Channel Development Trend
FIG NO. 49. Growth in World Gross Product, 2008-2018
FIG NO. 50. Research Methodology – Detailed View
FIG NO. 51. Research Methodology
 
 

Table Of Tables

List of Tables 

TABLE NO. 1. Global Artificial Intelligence (AI) In Drug Discovery Market: Snapshot
TABLE NO. 2. Quarterly Artificial Intelligence (AI) In Drug Discovery Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Artificial Intelligence (AI) In Drug Discovery Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
TABLE NO. 6. Global Artificial Intelligence (AI) In Drug Discovery Market for Large Molecules, by Region, 2016 – 2028 (USD Million)
TABLE NO. 7. Global Artificial Intelligence (AI) In Drug Discovery Market for Small Molecules, by Region, 2016 – 2028 (USD Million)
TABLE NO. 8. Global Artificial Intelligence (AI) In Drug Discovery Market for Software, by Region, 2016 – 2028 (USD Million)
TABLE NO. 9. Global Artificial Intelligence (AI) In Drug Discovery Market for Services, by Region, 2016 – 2028 (USD Million)
TABLE NO. 10. Global Artificial Intelligence (AI) In Drug Discovery Market for Immuno-oncology, by Region, 2016 – 2028 (USD Million)
TABLE NO. 11. Global Artificial Intelligence (AI) In Drug Discovery Market for Neurodegenerative Diseases, by Region, 2016 – 2028 (USD Million)
TABLE NO. 12. Global Artificial Intelligence (AI) In Drug Discovery Market for Cardiovascular Diseases, by Region, 2016 – 2028 (USD Million)
TABLE NO. 13. Global Artificial Intelligence (AI) In Drug Discovery Market for Metabolic Diseases, by Region, 2016 – 2028 (USD Million)
TABLE NO. 14. Global Artificial Intelligence (AI) In Drug Discovery Market for Other Applications, by Region, 2016 – 2028 (USD Million)
TABLE NO. 15. Global Artificial Intelligence (AI) In Drug Discovery Market for Pharmaceutical & Biotechnology Companies, by Region, 2016 – 2028 (USD Million)
TABLE NO. 16. Global Artificial Intelligence (AI) In Drug Discovery Market for Contract Research Organizations, by Region, 2016 – 2028 (USD Million)
TABLE NO. 17. Global Artificial Intelligence (AI) In Drug Discovery Market for Research Centers and Academic & Government Institutes, by Region, 2016 – 2028 (USD Million)
TABLE NO. 18. Global Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Region, 2016 – 2028 (USD Million)
TABLE NO. 19. North America Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 20. North America Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Drug Type, 2016 – 2028 (USD Million)
TABLE NO. 21. North America Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Offering, 2016 – 2028 (USD Million)
TABLE NO. 22. North America Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 23. North America Artificial Intelligence (AI) In Drug Discovery Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 24. U.S. Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Drug Type, 2016 – 2028 (USD Million)
TABLE NO. 25. U.S. Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Offering, 2016 – 2028 (USD Million)
TABLE NO. 26. U.S. Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 27. U.S. Artificial Intelligence (AI) In Drug Discovery Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 28. Canada Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Drug Type, 2016 – 2028 (USD Million)
TABLE NO. 29. Canada Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Offering, 2016 – 2028 (USD Million)
TABLE NO. 30. Canada Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 31. Canada Artificial Intelligence (AI) In Drug Discovery Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 32. Mexico Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Drug Type, 2016 – 2028 (USD Million)
TABLE NO. 33. Mexico Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Offering, 2016 – 2028 (USD Million)
TABLE NO. 34. Mexico Artificial Intelligence (AI) In Drug Discovery Market Revenue, By Application, 2016 – 2028 (USD Million)
TABLE NO. 35. Mexico Artificial Intelligence (AI) In Drug Discovery Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 36. Drivers for the Artificial Intelligence (AI) In Drug Discovery Market: Impact Analysis
TABLE NO. 37. Restraints for the Artificial Intelligence (AI) In Drug Discovery Market: Impact Analysis
TABLE NO. 38. Major Buyers of Artificial Intelligence (AI) In Drug Discovery
TABLE NO. 39. Distributors/Traders List of Artificial Intelligence (AI) In Drug Discovery
TABLE NO. 40. Global Artificial Intelligence (AI) In Drug Discovery Market, Company Market Revenue, 2016 – 2019 (USD Million)
TABLE NO. 41. Global Artificial Intelligence (AI) In Drug Discovery Market, Company Y-o-Y Growth, 2017 – 2019 (USD Million)